STOCKHOLM – February 27, 2020 – ContextVision, a medical technology software company specializing in image analysis and artificial intelligence, announced new growth within its market-leading medical image processing business. Newly signed customer contracts in both Asia and the United States are driving increased revenue in Q1 2020 and beyond. ContextVision continues to set the highest […]
STOCKHOLM – February 20, 2020 – ContextVision, a medical technology software company specializing in image analysis and artificial intelligence, today announced solid sales in Q4 to close out a record year for the company. With sales growth across its medical imaging offerings and patent approval for its unique method for high-quality digital pathology data generation, […]
ContextVision’s CEO Fredrik Palm discuss innovation around AI-powered diagnostic imaging and digital pathology at Sweden Korea Business Summit
“How AI transforms the Future Healthcare, Opportunities and Challenges” and discuss innovation around AI-powered diagnostic imaging and digital pathology.
ContextVision is pleased to announce that Arto Järvinen has been promoted to the company’s CTO position. Järvinen has been Director of R&D since 2011 and has been instrumental in leading the company’s operational R&D work. Järvinen has succeeded the former CTO and co-founder Martin Hedlund. Hedlund retired earlier this year but will resume in his board position for the company.
ContextVision announces first digital pathology patent granted for its unique and objective data-generation method
Master Annotation method has received patent protection in the U.S. The U.S. Patent and Trademark Office (USPTO) has granted a patent to ContextVision for this invention, titled “method and system for detecting pathological anomalies in a digital pathology image and method for annotating a tissue slide”.
ContextVision unveils latest innovation in advanced medical imaging At this year’s RSNA, ContextVision demonstrates Rivent™, taking image enhancement for ultrasound to a whole new level STOCKHOLM – Nov. 18, 2019 – ContextVision, a medical technology software company specializing in image analysis and artificial intelligence, provides cutting-edge technology to support clinicians to accurately interpret medical images, […]
ContextVision – Strong Q3 with solid sales, good inflow of new customers and first product in digital pathology enters beta-testing phase
ContextVision has seen a strong third quarter in 2019 as new customers have been added and the first product in digital pathology has entered the beta-testing phase. Q3 sales reached 23 MSEK and total sales are growing +5% compared to the third quarter last year. The operating result was positive 4.6 MSEK.
Nordnet have published an investor presentation of ContextVision. Please find the interview with CEO Fredrik Palm below (in Norwegian/Swedish) or follow this link.
ContextVision – Second quarter saw commercial release of first AI-based product, Altumira™, Digital Pathology on track and record sales
ContextVision’s AI-based product Altumira™ for X-ray is now commercially available and INIFY Prostate for digital pathology will soon move to beta testing in several pathology labs. Q2 sales reached 23,1 MSEK, record sales for second quarter, 5,5% higher than Q2 2018. The operating result was positive 5,4 MSEK, mainly due to higher capitalization for product development but also supported by strong sales performance.
ContextVision’s Deep Learning experts will hold an oral presentation at the Medical Imaging & Deep Learning conference in London July 8–10
This paper presents an interesting and novel idea of a deep learning (DL) framework to segment potentially cancerous areas in prostate biopsies using semi-automatically generated data. The application of this paper is quite innovative and the proposed method seems to be a direct assistance to the clinical routine.